Multiple sclerosis, relapsing.
Mechanism in the treatment of MS is unknown; however, it enhances suppressor T cell activity, reducing of proinflammatory cytokines, down-regulating of antigen presentation, and reducing trafficking of lymphocytes into the central nervous system. Improves MRI lesions, decreases relapse rate, and disease severity in patients with secondary progressive MS.
Adults/Geriatric:SubQ: Initial: 0.0625 mg every other day; gradually increase dose by 0.0625 mg every 2 weeks to a target dose of 0.25 mg every other day.
0.0625 mg = 2 million units
Doesn’t require dose adjustment for renal patients.
Doesn’t require dose adjustment for hepatic patients.
Ref.BNFLexicomp – Drug information handbookExtavia (interferon beta-1b) [prescribing information].Betaseron (interferon beta-1b) [prescribing information].